OPDIVO is indicated for the treatment of patients with classical Hodgkin Lymphoma (cHL) that has relapsed or progressed after Autologous Hematopoietic Stem Cell transplantation (HSCT) and post-transplantation brentuximab vedotin.

INN:

Subtype:

Hodgkin Lymphoma (HL)

License:

FDA

Class:

PD-1 inhibitor

R/R

PIhttp://packageinserts.bms.com/pi/pi_opdivo.pdf 

1. Approved Labelling 

Opdivo is indicated for the treatment of patients with classical Hodgkin Lymphoma (cHL) that has relapsed or progressed after Autologous Hematopoietic Stem Cell transplantation (HSCT) and post-transplantation brentuximab vedotin.

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

2. Treatment Regimen

The recommended dose of Opdivo is 3 mg/kg administered as an intravenous infusion over 60 minutes every 2 weeks until disease progression or unacceptable toxicity.

3. AE/Warnings 

Please see section 5 of the PI

 

All content on this site is intended for healthcare professionals only. If you are a patient or carer, please visit the Lymphoma Coalition.